Evidence map›Paper›PMID 40883777›Full record

ArticleBMC veterinary research2025

In vivo pharmacokinetic and pharmacodynamic profiles of orbifloxacin against Staphylococcus aureus in a neutropenic murine thigh infection model.

Long-Gen Zhong, Si-Jia Tang, Liu-Yan Liang, Xin Yao, Li-Wen Sun, Jian Sun, Xiao-Ping Liao, Yu-Feng Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Long-Gen ZhongState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Si-Jia TangState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Liu-Yan LiangState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Xin YaoState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Li-Wen SunState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Jian SunState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Xiao-Ping LiaoState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Yu-Feng ZhouState Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China. zyf@scau.edu.cn.

Funding

Foundation for Innovative Research Groups of the National Natural Science Foundation of China 32121004Guangdong Basic and Applied Basic Research Foundation 2024A1515010365Guangzhou Science and Technology Plan Project 2024A04J3412National Natural Science Foundation of China 32172909
6 · The paper itself

Abstract

backgroundOrbifloxacin is a broad-spectrum fluoroquinolone antibiotic developed for veterinary use in the treatment of skin and soft tissue infections, as well as respiratory tract infections. This study aimed to define the pharmacokinetic/pharmacodynamic (PK/PD) indices and target exposures associated with antibacterial activity, thereby providing a rational framework for the development and optimization of orbifloxacin dosing regimens in the treatment of Staphylococcus aureus infections.

resultsThe PK profiles and PK/PD relationship of orbifloxacin against S. aureus were investigated using a neutropenic murine thigh infection model with multiple dosing regimens. Orbifloxacin exhibited a short-duration post-antibiotic effect (PAE; 0.12–2.45 h) and a longer post-antibiotic sub-MIC effect (PA-SME; 2.13–5.29 h) against S. aureus. The dose-response analysis indicated that the area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) ratio over 24 h (AUC24h/MIC) was a strong PK/PD index predictive of antibacterial efficacy (R² >0.98). AUC24h/MIC targets of 33.78–37.79 h, 53.30–61.56 h, 88.59–98.35 h, and 179.43–217.47 h were required to achieve bacteriostatic, 1-log10, 2-log10, and 3-log10 bacterial reductions, respectively.

conclusionsThe results confirm that AUC24h/MIC is an appropriate PK/PD index for predicting antibacterial efficacy and establish target exposure values required to achieve various levels of bacterial kill.

Indexed as

Anti-Bacterial AgentsCiprofloxacinStaphylococcal InfectionsStaphylococcus aureusAnimalsArea Under CurveDose-Response Relationship, DrugFemaleMiceMicrobial Sensitivity TestsNeutropeniaThighAnti-Bacterial AgentsCiprofloxacinorbifloxacinOrbifloxacinPK/PDPK profileStaphylococcus aureus

Identifiers

PMID40883777
PMCPMC12395723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.